Skip to main content
OpenTrials
Completed

NCT Number: NCT01916057

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis

The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Chronic disseminated candidiasis, often referred to as hepatosplenic candidiasis (HSC), is an infection due to Candida spp. that mainly involves the liver and spleen. HSC occurs mostly in patients with profound and prolonged neutropenia, which is more often seen in patients with hematologic malignancies. Despite an appropriate antifungal prophylaxis, the incidence of HSC in France might be closed to 5% in patients suffering from acute leukemia. Early and adequate diagnosis and treatment of HSC are crucial, as treatment delays can negatively affect the prognosis of the underlying condition. Current guidelines recommend a 6-month duration treatment. Prolonged treatments up to 6 months are frequent, leading to antifungal toxicity and cost increase. Preliminary study by our team has already assessed F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) as a diagnostic tool for HSC. 18F-FDG PET scan could be helpful in the diagnosis, follow-up and therapy strategy of HSC, helping to stop antifungal treatment. Other molecular, immunological and serological tools have to be developed in order to avoid hepatic biopsies. Actually, mycological evidence of infection is found in only 20% of the cases. The pathogenesis of HSC is also not well understood, but it is believed that it may be due to an unbalanced adaptive immune response that leads to an exacerbated inflammatory reaction, resulting in an Immune Reconstitution Inflammatory Syndrome (IRIS). In that context, a better understanding of the disease pathophysiology and of the potential genetic susceptibility could have an impact on therapy strategy. For example, new approaches such as the use of adjuvant high-dose corticosteroids have been shown beneficial. This study is the first step to improve HSC diagnosis and therapy strategy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patients' inclusion criteria:

  • Adults aged ≥18 years-old
  • Hospitalized for hematological malignancy or hematopoietic stem cell transplantation
  • Recent (>2months), prolonged (>10 days), profound (>100 PMN/mm3), feverish neutropenia
  • Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT)

Patients' exclusion criteria:

  • hepatosplenic lesions of other proven origin

Patients' non-inclusion criteria:

  • Life expectancy >3 months
  • Pregnancy
  • HIV infection
  • Hepatic biopsy within 3 weeks before 18F-FDG PET scan

Treatment and study plan

18F-FDG PET Scan

Device

to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.

Primary outcomes

  1. Global response to therapy

    Time frame: at month 3

    Clinical assessment (no fever) and PET scan assessment (intensity of liver and/or spleen lesions)

Secondary outcomes

  1. 18F-FDG PET scan and RMI usefulness in initial diagnosis

    Time frame: at month 3

    Comparison between Day 0 and Month 3 exams

  2. Serological and molecular mycological tools assessment

    Time frame: at day 0

    Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.

    Assessment of a new real-time PCR on serum and hepatic tissue

  3. Serological and molecular mycological tools assessment

    Time frame: at Month 3

    Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.

    Assessment of a new real-time PCR on serum and hepatic tissue

  4. Serological and molecular mycological tools assessment

    Time frame: at Month 6

    Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls.

    Assessment of a new real-time PCR on serum and hepatic tissue

  5. Inflammatory cells and mediators

    Time frame: at day 0

    Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls

  6. Inflammatory cells and mediators

    Time frame: at month 3

    Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls

  7. Inflammatory cells and mediators

    Time frame: at month 6

    Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls

  8. Genetic susceptibility

    Time frame: at day 0

    Search for susceptibility genes to candidiasis in comparison with controls

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France
  • Institut Pasteur
  • URC-CIC Paris Descartes Necker Cochin
  • University Hospital, Lille
  • University of Lausanne Hospitals

Registry information

Official study title

Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis

Acronym: CANHPARI

Important dates

Study start
2013
Primary completion
2017
Study completion
2018
First posted
Aug 5, 2013
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.